90 percent effective is nice, but then in 4/5 months your back to zero again just like flu vaccine those antibodies go away, so then in month 5 you need another vaccine, and again and again and again, there is never ever talk about long term memory, why? Because they have none, so here’s the big problem with this scenario and get ready if I’m right which I know I am as I’ve been right about everything since February, you get vaccine over and over and over again, then maybe you get COVID just like flu over and over again, but because vaccine it’s less systematic and extreme just like flu scenario, because flu is only 37 percent on that vaccine and also the antibodies leave that’s why you need it yearly and let’s not forget flu is seasonal, Covid is not, so flu you need 1 vaccine a year, Covid 3 times a year, so here is when death really starts occurring which also no one wants to talk about but I will because THIS IS REALITY, vaccine over vaccine over vaccine, Covid potential over potential, no long term memory, this means 1791 bad buys (non neutralizing antibodies out of 1800 Covid or the mRNA, DNA, RNA vaccines give you ( this is disgusting), this is the death part, they build up as protein in the body, over and over and over again based on how many vaccinations you get, how many times you get Covid in between, that buildup creates off targets from Isle 5, TH2 from the full spike protein, and that’s when the off targets really start, the cytokine storm, RHF in children, and about 30/40 other off targets responses as well as auto immune problems where your own immune system attack your body, this is a xxxxxxx xxxx only choosing Gene Therapy Pathways (RNA, mRNA and DNA), and who on the planet is putting a Gene therapy in a newborn, infant, child, adolescent, teen, pregnant woman when Gene therapy will disrupt Gene growth in these immature sensitive groups with immature immune systems.
I know this is from Joe's personal FB page but it is
90 percent effective is nice, but then in 4/5 months your back to zero again just like flu vaccine those antibodies go away, so then in month 5 you need another vaccine, and again and again and again, there is never ever talk about long term memory, why? Because they have none, so here’s the big problem with this scenario and get ready if I’m right which I know I am as I’ve been right about everything since February, you get vaccine over and over and over again, then maybe you get COVID just like flu over and over again, but because vaccine it’s less systematic and extreme just like flu scenario, because flu is only 37 percent on that vaccine and also the antibodies leave that’s why you need it yearly and let’s not forget flu is seasonal, Covid is not, so flu you need 1 vaccine a year, Covid 3 times a year, so here is when death really starts occurring which also no one wants to talk about but I will because THIS IS REALITY, vaccine over vaccine over vaccine, Covid potential over potential, no long term memory, this means 1791 bad buys (non neutralizing antibodies out of 1800 Covid or the mRNA, DNA, RNA vaccines give you ( this is disgusting), this is the death part, they build up as protein in the body, over and over and over again based on how many vaccinations you get, how many times you get Covid in between, that buildup creates off targets from Isle 5, TH2 from the full spike protein, and that’s when the off targets really start, the cytokine storm, RHF in children, and about 30/40 other off targets responses as well as auto immune problems where your own immune system attack your body, this is a xxxxxxx xxxx only choosing Gene Therapy Pathways (RNA, mRNA and DNA), and who on the planet is putting a Gene therapy in a newborn, infant, child, adolescent, teen, pregnant woman when Gene therapy will disrupt Gene growth in these immature sensitive groups with immature immune systems.
Top 10 Most Recent News Articles
NAMSA, AMS Partner to Fast-Track Tissue-Healing Tech
Streamlining the Path to Market I tell you, the medical device sector is no walk in the park these days. Between the regulators breathing down your neck and the endless red tape, getting a new product from the lab to the hospital floor can feel like running a marathon in quicksand. That's why this deal between NAMSA and Advanced Medical Solutions (AMS) has me taking a...
Continue Reading
VILVA's Global Reach: Power Testing's Next Phase
A Power Play on Global Markets Taking a page from its relentless pursuit of quality and innovation, VILVA Electronics is bolstering its foothold on the international stage. Based in Shenzhen, this savvy player is reaching out for strategic partners like fishing for that perfect bite, hoping to reel in catches that understand the nitty-gritty of the local ponds—their...
Continue Reading
AI Faces Accountability Trials in Business 2027
Charting the AI Accountability Course In 2027, the corporate AI landscape won't be the Wild West anymore; it's morphing into a structured battlefield where the winners will be those who successfully enforce accountability. The hands-off, carte blanche days of AI are fading fast, and businesses are starting to scrutinize the AI tools they've been throwing money at. "The...
Continue Reading
Global Vineyards List: New Entrants & Rankings Unveiled
Vineyards' Global Ranking Unveiled Wine enthusiasts and globetrotters have something to toast about this November. The 50 Best Vineyards just expanded its ranking to reveal the vineyards sitting in spots 51 through 100 for 2026. This list, spotlighting some of the globe's finest wine destinations, precedes the main awards ceremony set for November 18 in Santiago, Chile....
Continue Reading
Net at Work Enhances Offering with K&R Acquisition
Net at Work Makes a Strategic Move Out of the blue, Net at Work, a prominent figure in the North American tech scene, zeroes in on boosting their expertise with the acquisition of K&R Consulting Group. It's all about expanding their horizons, and snagging K&R doesn't just double down on their ERP game, it broadens their client base in manufacturing, distribution, and...
Continue Reading
Goodyear's Strategic Shift: New Leadership, New Path
Big Shoes, Bigger Expectations Who's steering the Goodyear ship now that Mark Stewart's out the door? Roger Wood's the name, interim CEO is the game. Don't fret too much—the board's hustling to nail down a permanent top dog. But this isn't a musical chairs game; it's a full-on strategic shift. Goodyear's forming committees, juggling ideas, and ripping through their...
Continue Reading
Zions Bank Spurs Idaho's Small Biz Boom in 2026
Riding the Small Business Tsunami in Idaho You don't hear it every day, but Idaho's small business scene is hotter than a frypan—a nod to the entrepreneurial fire blazing in the state, and Zions Bank is holding the torch. In 2026, despite dealing with the uphill battles of inflation, tariffs, and labor scarcity, those entrepreneurs still managed to carve out a spot at...
Continue Reading
California Credit Union's Toy Drive Brings Holiday Cheer
California Credit Union Joins Forces for Holiday Toy Drive Alright, folks, here’s a story with a feel-good spin straight out of Glendale. California Credit Union is at it again, teaming up with the Los Angeles Boys & Girls Club to sprinkle some holiday magic on local kiddos and their families. Now, it’s the sixth year straight they’ve pulled off this toy drive...
Continue Reading
Veterinary Stories Transform Pet Care in New Docuseries
Peeling Back the Scrubs: Hidden Heroes in Vet Medicine Everyone's all-hands-on-deck when it's your furball on the line, but how much do you really know about what happens in those vet offices? Finally, National Veterinary Associates (NVA) is unzipping that mystery with a no-bones-about-it docuseries, Advancing Veterinary Medicine: Our Stories, right out of Austin, Texas....
Continue Reading
Inside Kristallnacht: An XR Journey for a New World
Bridging the Past with Powerful Tech: A Journey to Kristallnacht Let's cut to the chase: if there's a time in history that we all need to sear into our collective consciousness, it's Kristallnacht. Forget the mere notion of reading it from a textbook; now you can dive headfirst into the harrowing events of November 9, 1938, thanks to the cutting-edge initiative inside...
Continue ReadingTop 5 Most Recently Viewed Articles
Getinge's Early 2025 Financial Results: Insights and Strategies
Sales Growth and Performance Overview Getinge has reported a strong performance for the first quarter of 2025, characterized by an organic sales growth of 6.2%. Despite facing currency headwinds, the medical technology company's positive trajectory continues to impress. The rise in order intake, marked at 2.9%, further cements Getinge's position as a key player in the...
Continue Reading
UnitedHealth's 2025 Outlook: Insights Amid Industry Challenges
UnitedHealth's Anticipated 2025 Outlook Investors eagerly await significant insights into UnitedHealth Group's (NYSE: UNH) projections for 2025 as the company prepares to release its quarterly results. This anticipation follows the recent tragic event involving executive Brian Thompson, whose murder led to the cancellation of crucial investor day presentations. With the...
Continue Reading
Industrial Nitrogen Market Poised for Significant Growth Ahead
The Promising Future of the Industrial Nitrogen Market Recent analyses indicate a bright future for the global industrial nitrogen market, which is anticipated to reach a value of USD 38.29 billion in the next few years. This projection reflects a strong compound annual growth rate (CAGR) of 6.1% based on recent evaluations. The growth trend is largely driven by...
Continue Reading
Akeso Showcases Groundbreaking IL-1RAP Antibody Research
Akeso Showcases Groundbreaking IL-1RAP Antibody Research Akeso, Inc. (HKEX: 9926.HK) has unveiled promising data from preclinical studies of a new monoclonal antibody known as AK135. This innovative treatment specifically targets the IL-1 receptor accessory protein (IL-1RAP) and effectively blocks multiple pro-inflammatory pathways. The recent findings were presented at a...
Continue Reading
Vor Bio's Pioneering Research in IgA Nephropathy Presentation
Vor Bio Unveils Groundbreaking IgA Nephropathy Study at ASN 2025 CAMBRIDGE, Mass. -- Vor Bio, a leader in clinical-stage biotechnology focused on autoimmune diseases, is set to make a significant impact at the upcoming American Society of Nephrology’s Kidney Week 2025. They will present clinical data from a Phase 3 study conducted in collaboration with RemeGen Co., Ltd,...
Continue Reading